99% Pure Sitagliptin CAS 486460-32-6 in Stock
Product Description
Sitagliptin, trade name Genover, is an oral hypoglycemic agent (antidiabetic drug), which belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor, produced by Merck R&D and sales. Sitagliptin can be used alone or combined with other oral hypoglycemic drugs to form a compound drug (such as metformin or thiazolidinedione) to treat type 2 diabetes. The advantage of sitagliptin is that it has fewer side effects (such as a lower chance of causing hypoglycemia and weight gain) when controlling the blood glucose level. Although safety is its advantage, the effect cannot be well guaranteed, so it is generally recommended to use it in combination with other drugs such as metformin.
| Product Name | Sitagliptin |
| MOQ | 1kg |
| CAS | 486460-32-6 |
| Appearance | white |
| Molecular Formula | C16H15F6N5O |
| Molecular Weight | 407.31 |
| Assay | >99% |
| Application | For research purpose only |
| Packing | 25kg/drum |
| Storage | Store in a well-closed,light-resistant container |
| Custom synthesis | Available |
Function and Application
Sitagliptin is a new type of anti-type II diabetes drug approved by the FDA and the first dipeptidyl peptidase-IV inhibitor drug for the treatment of type II diabetes. Sitagliptin's mechanism of action is different from previous oral hypoglycemic drugs. It improves the ability of diabetic patients' own pancreatic β cells to produce Chemicalbook in-sulin, and increases the secretion of in-sulin when blood sugar rises, thereby controlling the blood sugar level of diabetic patients. Clinical studies have shown that sitagliptin is an oral effective drug with good market prospects. It has a significant hypoglycemic effect when used alone or in combination with metformin and pioglitazone, and it is safe to take, well tolerated, and has fewer adverse reactions.
